SCHEMBL16017663

SCHEMBL16017663

Cc1ccccc1C(=O)N1CCc2ccccc2C1CN1C(=O)c2ccccc2C1=O

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
NPSR1 Q6W5P4 2/20 0.62
KEAP1 Q14145 13/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
NFE2L2 Q16236 6/20 0.59
MAPK1 P28482 1/20 0.59
ATM Q13315 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
MAPT P10636 2/20 0.54
LMNA P02545 1/20 0.54
RECQL P46063 1/20 0.54
CYP3A4 P08684 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14921954 0.88 KEAP1 (0.66) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2
SCHEMBL18066433 0.83 KEAP1 (0.73) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2
SCHEMBL16017668 0.80 MAPK1 (0.67) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2
SCHEMBL16017654 0.79 ALDH1A1 (0.66) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2
SCHEMBL16017669 0.78 MAPK1 (0.65) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2
SCHEMBL14921422 0.78 ALDH1A1 (0.62) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2
SCHEMBL18085751 0.78 ALDH1A1 (0.62) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2
SCHEMBL14921353 0.78 MAPK1 (0.67) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2
SCHEMBL14921399 0.77 ALDH1A1 (1.00) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2
SCHEMBL14921401 0.77 ALDH1A1 (1.00) ALDH1A1NPSR1KEAP1SMN1; SMN2NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148408-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2018-05-31 US disclosed
US-20140256767-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS THE BROAD INSTITUTE, INC. (US) 2014-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148408-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS KEAP1, NFE2L2, HMOX1 ALDH1A1 1021/4885NPSR1 3759/4885KEAP1 1/4885
US-20140256767-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS KEAP1, NFE2L2, HMOX1 ALDH1A1 1021/4885NPSR1 3759/4885KEAP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.